Rafael Holdings, Inc. (RFL)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Rafael Holdings, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 1.90 $ — 27% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralGeprüft am 13.07.2026 gegen die beiden Geschäftsberichte (10-K) für die Geschäftsjahre 2025 (eingereicht 29.10.2025) und 2024 (07.11.2024) sowie die vier jüngsten Quartalsberichte (10-Q) bis zum 30.04.2026: In sämtlichen ausgewerteten SEC-Filings von Rafael Holdings findet sich kein einziger belastbarer KI-Bezug — weder „artificial intelligence“ noch „machine learning“, „generative“ oder „large language model“ tauchen im Geschäftsmodell, in der Segmentberichterstattung oder in den Risk Factors auf. Rafael Holdings ist eine Biotech-Beteiligungs-Holding: Kerngeschäft ist die Entwicklung des Wirkstoffs Trappsol® Cyclo™ gegen die seltene Kinderkrankheit Niemann-Pick Typ C1 (über die 2025 übernommene Cyclo Therapeutics) sowie Minderheits- und Mehrheitsbeteiligungen an weiteren Pharma- und Medizingeräte-Firmen; dazu kommt eine einzige Rest-Immobilie in Jerusalem. KI ist weder Umsatzquelle noch dokumentierter operativer Hebel noch ein im 10-K konkret benanntes Geschäftsrisiko fürs eigene Modell. Nach dem Kriterienkatalog (Vorrang verkauft > bedroht > nutzt > neutral) bleibt es damit klar bei „neutral“ — dokumentierter Negativ-Befund, keine belastbaren Treffer in den geprüften Filings.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-K 2025-10-29 · 10-K 2024-11-07 · 10-Q 2026-06-11 · 10-Q 2026-03-16 · 10-Q 2025-12-12 · 10-Q 2025-06-11
Rated on July 13, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2025: Q1 | -0.09 | -176.70 | 0 | 13.20 | -6,027.30 | -2 | -2 |
| 2025: Q2 | -0.09 | – | 0 | 7.70 | -1,320.20 | -3 | -3 |
| 2025: Q3 | -0.24 | – | 0 | 112.10 | -3,455.40 | -10 | -10 |
| 2025: Q4 | -0.19 | – | 0 | 87.50 | -4,090.00 | -7 | -7 |
| 2026: Q1 | -0.13 | – | 0 | 174.00 | -3,041.20 | -8 | -8 |
| 2026: Q2 | -0.08 | – | 0 | -50.60 | -2,360.90 | -7 | -7 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Rafael Holdings, Inc. hält in erster Linie Beteiligungen an Pharmaunternehmen in der klinischen und Frühphase sowie an Medizinprodukten in den USA und Israel.
| Employees | 21 |
|---|---|
| Headquarters | Newark, NJ |
| Website | rafaelholdings.com |
| IPO Date | 26. Mar 2018 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Howard S. Jonas | CEO, President, Founder & Executive Chairman | 1956 |
| David A. Polinsky Esq. | Chief Financial Officer | 1972 |
| Joshua M. Fine | Chief Operating Officer | 1982 |
| Joyce J. Mason Esq. | Corporate Secretary | 1959 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 29. Jul 2026 | Jonas Howard S | Exec Chairman, CEO & President | Other | 54,945 | 2.73 | 150,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.